Interview
Preventing lead poisoning for $1.66 per child | Lucia Coulter
- Toxicity Magnitude: Lead mimics essential calcium ions, interfering with subcellular processes in every organ system; humans lack biological mechanisms to eliminate it, causing it to accumulate in bones and tissues for decades.
- Neurological Impact: Average blood lead levels of 5 µg/dL in low- and middle-income countries (LMICs) cause a 1–6 point IQ reduction, equivalent to approximately one year of lost schooling and significant future earnings loss.
- Mortality Estimates: Lead exposure causes an estimated 1.6 to 5.5 million cardiovascular deaths annually globally, the vast majority in LMICs; a recent World Bank report estimates lead reduces healthy life expectancy by 7% of global GDP.
- Comparative Risk: Children in LMICs average 5 µg/dL blood lead levels (classified as poisoning), whereas high-income countries average ~1 µg/dL; 66% of children in India have levels deemed toxic in the US.
- Malawi Intervention Success: LEAP tested 57% of paint brands in Malawi for lead; 100% of samples with lead contained 10,000 parts per billion (100x the safe limit), prompting immediate government regulation and a market shift to lead-free options.
- Cost-Effectiveness Data: LEAP estimates the cost of preventing one child's lead exposure at $1.66 (Founders Pledge analysis) or $14 per disability-adjusted life year (DALY) averted, making it one of the most cost-effective global health interventions known.
- Exposure Sources: Primary sources in LMICs include leaded paint (approx. 7–20% of exposure), aluminum cookware (often from recycled lead), lead-glazed ceramics, lead-adulterated spices (e.g., turmeric for color), and cosmetics like kohl eyeliner.
- Scalability Goals: With a $20 million funding target over 5–7 years, LEAP aims to remove leaded paint from 50+ countries, covering 90% of the child population in LMICs; current funding is $1M/year with a $2.5M gap.
- Regulatory Strategy: Success relies on providing low-cost data (paint studies costing <$5,000), technical assistance for reformulation, and funding for multi-stakeholder meetings, rather than traditional advocacy.
- Alternative Interventions: LEAP is exploring lead in spices (Bangladesh/Turmeric), cosmetics (Pakistan kohl), and cookware, but paint remains the highest priority due to tractability and data availability.
- Technological Needs: Portable X-ray fluorescence (XRF) devices are crucial for enforcement but lack regulatory approval due to precision issues; accurate, low-cost blood lead testing would be a "game-changer" for public awareness.
- Funding History: LEAP was initially rejected by GiveWell in 2020 due to data uncertainty and lack of immediate tractability evidence; Open Philanthropy funded the organization in 2023 after updated evidence on mortality and tractability.
- Founder Background: Dr. Lucia Coulter is a former UK NHS doctor who founded LEAP via the Charity Entrepreneurship incubation program, pledging 10% of her income to effective charities via Giving What We Can.
- Future Hiring: LEAP is recruiting project managers starting December 20th, aiming to expand operations and support the scaling of regulatory enforcement in target countries.